Get the app
USHealthcare

Prestige Brand Holdings Inc (PBH)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$46.47-0.83%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
$265.7M
Revenue YoY
+6.5%
Net profit
$29.2M
Profit YoY
-38.5%
EPS
$0.98
EPS estimate
$0.89
Net margin
11.0%

EPS came in at 0.98 against a street estimate of 0.89 — a beat of 10.1%.

Key statistics

Market cap
$2.26B
P/E
13.3
Forward P/E
10.5
P/B
1.16
Book value
$40.46
EPS (TTM)
$3.57
52-week high
$71.07
52-week low
$42.62
50-day MA
$50.74
200-day MA
$56.58
Beta
0.33

Analyst view

Analysts rate Prestige Brand Holdings Inc a buy (3 buy, 3 hold, 1 sell out of 7) with an average price target of $67.80.

From the latest earnings call · 2026-08-06

MIXED Q2 organic growth slowed to 6% in Specialty Foods; major QSR and retail launches deferred to Q4/early 2027. EBITDA guidance cut $30M due to timing, not fundamentals. Strong U.S. protein growth and robust pipeline offset capacity headwinds. Q2 2026 U.S. business fundamentals strong; Canada facing near-term headwinds but strategic consolidation underway. Analysts pressed on timing and competitiveness of Specialty Foods slowdown; management deflected to temporary LTO deferrals and customer internal issues, not market loss. Street focused on leverage path and Stampede excess capacity; PBH targeting 3x+ by early-mid 2027, no lower-bound commitment. 2026-08-06…

Full summary in the app.

Shareholding

Insiders
1.41%
Institutions
116.28%

Largest institutional holders

FundStake
BlackRock Inc15.60%
Ariel Investments, LLC10.28%
Vanguard Portfolio Management, LLC5.92%
Dimensional Fund Advisors, Inc.5.62%
Kayne Anderson Rudnick Investment Management LLC4.65%
Vanguard Capital Management, LLC4.42%
Brandes Investment Partners & Co4.33%
State Street Corp4.16%

Recent filings & reports

DocumentDate
Board / officer change · Q2 FY2027
PRESTIGE CONSUMER HEALTHCARE INC. (PBH) - FORM 8-K SUMMARY Filing Date: August 10, 2026 --- OTHER NOTABLE POINTS • Jeffrey Zerillo, Senior Vice Pre
2026-08-14
Quarterly report · Q1 FY2027
PRESTIGE CONSUMER HEALTHCARE INC. - Q1 FY2027 (ENDED JUNE 30, 2026) SUMMARY HEADLINE NUMBERS • Total Revenues: $265.7 million (Q1 2026) vs. $249.5 m
2026-08-06
Results announced · Q2 FY2027
PRESTIGE CONSUMER HEALTHCARE INC. - Q1 FY2027 EARNINGS SUMMARY HEADLINE NUMBERS • Q1 FY2027 revenue of $265.7 million, up 6.5% year-over-year from $
2026-08-06
Material agreement · Q2 FY2027
PRESTIGE CONSUMER HEALTHCARE INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company issued $400.0 million in senior notes on July 15, 2026 • Notes carry
2026-07-15
Material agreement · Q1 FY2027
PRESTIGE CONSUMER HEALTHCARE INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company borrowed $95,000,000 under amended Term Loan Credit Agreement on Jul
2026-07-06
Proxy statement · Q1 FY2027
PRESTIGE CONSUMER HEALTHCARE INC. - PROXY STATEMENT SUMMARY --- HEADLINE NUMBERS • Revenue of $1,089M in fiscal 2026 • Adjusted Diluted EPS of $4.3
2026-06-29
Annual report FY2026
PRESTIGE CONSUMER HEALTHCARE INC. - FISCAL YEAR 2026 SUMMARY HEADLINE NUMBERS • Fiscal year ended March 31, 2026 • Market capitalization: $2,970.2 m
2026-05-14
Quarterly report · Q3 FY2026
PRESTIGE CONSUMER HEALTHCARE INC. – QUARTERLY SUMMARY (Q3 FY2026) HEADLINE NUMBERS • Net Sales (9 months): $806.1 million vs. $840.4 million prior y
2026-02-05

Readable in the app.

Deals & corporate news

AnnouncementDate
Acquisition of LaCorium Health Australia and related entities completed
Prestige Consumer Healthcare completed its acquisition of LaCorium Health (an Australian company) on July 1, 2026. To finance this deal, the company borrowed $95 million under an amended ter
2026-07-06
Term loan facility arranged to finance acquisition transactions
Prestige Consumer Healthcare borrowed $1.045 billion through a new term loan on June 12, 2026, to finance unspecified transactions that closed that day. The company also secured an additiona
2026-06-16
Acquisition of Australian therapeutic skin care company for approximately $150 million
Prestige Consumer Healthcare Inc. announced it will acquire five Australian skincare companies (including LaCorium Health Australia and Laderma Holdings) for approximately $150 million in ca
2026-05-13
Definitive agreement to acquire over-the-counter consumer health products portfolio
Prestige Consumer Healthcare Inc. announced on March 19, 2026 that its subsidiary will acquire a portfolio of over-the-counter consumer health products from Foundation Consumer Brands for $1
2026-03-20

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Prestige Brand Holdings Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.